Cyclo Therapeutics Stock Today
| CYTH Stock | USD 0.73 0.03 4.29% |
Performance0 of 100
| Odds Of DistressOver 81
|
Cyclo Therapeutics is trading at 0.73 as of the 25th of November 2024. This is a 4.29 percent increase since the beginning of the trading day. The stock's open price was 0.7. Cyclo Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Cyclo Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of October 2024 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 23rd of February 2011 | Category Healthcare | Classification Health Care |
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida. Cyclo Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. The company has 28.77 M outstanding shares of which 114.42 K shares are currently shorted by private and institutional investors with about 3.82 trading days to cover. More on Cyclo Therapeutics
Moving against Cyclo Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Cyclo Stock Highlights
| Old Name | Lumen Technologies Inc | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCyclo Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cyclo Therapeutics' financial leverage. It provides some insight into what part of Cyclo Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Cyclo Therapeutics (CYTH) is traded on NASDAQ Exchange in USA. It is located in 6714 NW 16th Street, Gainesville, FL, United States, 32653 and employs 8 people. Cyclo Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 21 M. Cyclo Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 28.77 M outstanding shares of which 114.42 K shares are currently shorted by private and institutional investors with about 3.82 trading days to cover.
Cyclo Therapeutics currently holds about 4.29 M in cash with (16.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.51.
Check Cyclo Therapeutics Probability Of Bankruptcy
Ownership AllocationCyclo Therapeutics holds a total of 28.77 Million outstanding shares. Cyclo Therapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cyclo Ownership Details
Cyclo Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Wells Fargo & Co | 2024-06-30 | 4.4 K | |
| Princeton Global Asset Management Llc | 2024-09-30 | 3.5 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.1 K | |
| Royal Bank Of Canada | 2024-06-30 | 746 | |
| Bank Of America Corp | 2024-06-30 | 210 | |
| Jpmorgan Chase & Co | 2024-06-30 | 153 | |
| Steward Partners Investment Advisory, Llc | 2024-06-30 | 90.0 | |
| Advisor Group Holdings, Inc. | 2024-06-30 | 67.0 | |
| Qube Research & Technologies | 2024-06-30 | 21.0 | |
| Epiq Capital Group, Llc | 2024-09-30 | 739.4 K | |
| Vanguard Group Inc | 2024-09-30 | 598.7 K |
Cyclo Therapeutics Historical Income Statement
Cyclo Stock Against Markets
Cyclo Therapeutics Corporate Management
| Michael Lisjak | Global Development | Profile | |
| Lise MD | Chief Officer | Profile | |
| George Fails | Ex Mang | Profile | |
| Jeffrey Tate | Chief COO | Profile | |
| Scott Fine | CEO Director | Profile | |
| Lori McKenna | Global Advocacy | Profile | |
| E Strattan | Founder Director | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclo Therapeutics. If investors know Cyclo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.90) | Revenue Per Share 0.046 | Quarterly Revenue Growth 0.051 | Return On Assets (2.82) | Return On Equity (226.64) |
The market value of Cyclo Therapeutics is measured differently than its book value, which is the value of Cyclo that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclo Therapeutics' market value can be influenced by many factors that don't directly affect Cyclo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.